Search

Cancer, as a complicated disease, is considered to be one of the major leading causes of death globally. Although various cancer therapeutic strategies have been established, however, some issues confine the efficacies of the treatments. In recent decades researchers for finding efficient therapeutic solutions have extensively focused on the abilities of stem cells in cancer inhibition. Mesenchymal stem cells (MSCs) are multipotent stromal cells that can the most widely extracted from various sources such as the bone marrow (BM), placenta, umbilical cord (UC), menses blood, Wharton's jelly (WJ), adipose tissue and dental pulp (DP). These cells are capable of differentiating into the osteoblasts, chondrocytes, and adipocytes. Due to the unique characteristics of MSCs such as paracrine effects, immunomodulation, tumor-tropism, and migration, they are considered promising candidates for cancer therapeutics. Currently, MSCs are an excellent living carrier for delivery of therapeutic genes and chemical agents to target tumor sites. Also, exosomes, the most important extracellular vesicle released from MSCs, act as a strong cell-free tool for cancer therapeutics. MSCs can prevent cancer progression by inhibiting several signaling pathways, such as wnt/β-catenin and PI3K/AKT/mTOR. However, there are several challenges associated with the use of MSCs and their exosomes in the field of therapy that need to be considered. This review explores the significance of MSCs in cell-based therapy, focusing on their homing properties and immunomodulatory characteristics. It also examines the potential of using MSCs as carriers for delivery of anticancer agents and their role in modulating the signal transduction pathways of cancer cells. [ABSTRACT FROM AUTHOR]

Meningitis and meningoencephalitis, as inflammatory diseases of the brain parenchyma, are serious events reported sporadically after coronavirus disease 2019 (COVID-19) vaccination. However, there is a lack of systematic reviews consolidating these reported cases. By using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was conducted across PubMed, Scopus, Embase, and Web of Science databases. All case reports and series discussing the emergence of meningitis and meningoencephalitis after COVID-19 vaccination were included and evaluated using the Joanna Briggs Institute critical appraisal tool. Out of 967 records, 27 studies with 31 patients were eventually included. The most commonly reported symptoms were headaches and fever. About one-third of the patients exhibited positive meningeal signs. Most of the findings in the computed tomography scans and magnetic resonance images revealed no significant changes or enhancement in the leptomeninges. Cerebrospinal fluid analysis dominantly suggested aseptic meningitis, and about 80.6% of the patients experienced a full recovery. After a detailed review of the reported cases, further research is needed to establish a definitive correlation between meningitis and COVID-19 vaccination on a larger scale.